Auxilius Notes

Auxilius Completes SOC 2 Type 2 Certification

Third party audit demonstrates that Auxilius manages data with the highest standard of security and compliance.

NEW YORK -- Auxilius, leading provider of cloud-based software as a service (SaaS) for clinical trial financial management, successfully completed the Service Organization Control (SOC) 2 Type 2 audit.  Conducted by Geels Norton PLLC, an independent data security compliance and advisory firm, the audit validates the enterprise-level security for customer data within Auxilius’ operating environment, meeting the high bar for SOC 2 standards.
Innovative biotechnology companies operate within the intersection of rigorous regulations and increasingly automate activities that are core to financial and clinical operations. It is crucial that vendors demonstrate the ability to securely handle and manage sensitive information. Auxilius’ SOC 2 Type 2 report attests to the organizational controls around data security, availability, processing integrity, confidentiality, and privacy.
Auxilius is proud to provide life science innovators with trust and transparency into operating processes, data storage, confidentiality, security, privacy, and controls.
SOC 2 Type 2 certification demonstrates to current and future customers that Auxilius manages their data with the highest level of security.” says Adam Weisman, CEO and Co-Founder at Auxilius. “We have always ensured our platform’s security; Meeting the strongest standard for compliance, confirmed by a third-party audit, further verifies our pledge to customers." 

As life science companies increasingly leverage the Auxilius platform for enhanced control, accuracy, and efficiency in the end-to-end clinical trial finance continuum, reinforced trust and data integrity is of utmost importance.

About Auxilius

Auxilius is a software company designed to address the unique operational, financial, and accounting needs of clinical trials. The company has built FP&A and Accounting software that replaces manual processes and allows sponsors to take control over trial costs and clinical vendors through study-level budgeting, planning and financial close. Currently, the company works with a range of emerging and mature life science organizations.

For more information,, or follow on LinkedIn at